Open AccessPB2160 REAL LIFE EXPERIENCE OF TREATMENT WITH POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE COMBINATION IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Author(s) -
AlarcónPayer C.,
Sánchez M. E. Clavero,
Collado C. García,
Chacón M. Jurado,
Morales A. Jiménez
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000567124.09086.b6
Subject(s) - pomalidomide , lenalidomide , medicine , multiple myeloma , dexamethasone , bortezomib , oncology , cyclophosphamide , thalidomide , refractory (planetary science) , surgery , chemotherapy , physics , astrobiology
Background: Multiple myeloma is a plasma cell malignancy that accounts for 1% of all cancers. Despite available therapies, the disease remains uniformly fatal, and patients who have received prior lenalidomide and bortezomib have a median overall survival of 9 months. Pomalidomide and low‐dose dexamethasone (PomDex) is standard treatment of lenalidomide refractory myeloma patients who have received >2 prior therapies. Combination therapy is often used in clinical practice in an attempt to overcome drug/clone resistance. Aims: Evaluate in daily clinical practice the effectiveness and safety of the combination pomalidomide, cyclophosphamide and dexamethasone (PomCyDex) in adult patients with relapsed and refractory multiple myeloma (RRMM). Methods Four‐year prospective observational study on 33 cases of RRMM. To measure the health outcomes obtained with the PomCyDex combination in a third level hospital we used the median progression free survival (PFS) as the main variable to assess if the combination is effective. Age, number of previous treatment lines and most frequent adverse reactions were also measured. Results: 33 RRMM cases were analyzed, (57.6%: women; 42.4%: men). The mean age was 68 years. The health outcomes measured in our clinical practice were as follows: 39.4% of the patients were treated with PomCyDex in the 3rd line, 15.1% in the 4th line, 24.3% in the 5th line, 18.2% in the 6th line and 3% in the 7th line. The mean number of PomCyDex cycles received was 9. The median PFS was 5.5 months. PomCydex combination was shown to improve PFS by an additional 1.5 months compared to PomDex‐only patients receiving a 4 month PFS (MM‐003). The most frequent adverse reactions observed were neutropenia (38%), anaemia (11%) and thrombocytopenia (5%). Summary/Conclusion: Treatment with PomCyDex is an effective combination in the treatment of adult patients with RRMM. Also, PomCyDex combination is well tolerated in most patients and is therefore considered a safe treatment.